RxDoctor Payments Data

Mary Spolyar, MD

Procedural Dermatology · Indianapolis, INNPI 1932169349

Payments from drug & device makers

$17,118in general payments, 2019–2025

Across 882 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Boehringer Ingelheim$2K
  • Novartis$2K
  • Pfizer$1K
  • Incyte Corporation$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • plus $7K from 29 others

What the payments were for

  • Consulting fees$1,87511%
  • Food & beverage$14,65186%
  • Education$5913%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few procedural dermatology providers in Indianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$387,566
Medicare patients
1,406
Services billed
5,344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast37$173,542
Dupixent PenDupilumab24$99,077
Clobetasol Propionate129$6,600
Ketoconazole315$6,152
Metronidazole73$4,053
Tacrolimus40$3,889
Triamcinolone Acetonide256$2,180
Fluorouracil31$2,098
ValacyclovirValacyclovir Hcl83$1,666
Fluocinonide48$1,617
Doxycycline Hyclate70$1,608
Minoxidil129$1,049
Clindamycin Phosphate14$931
Tretinoin15$913
Minocycline Hcl17$604

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$844$173,54237 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few procedural dermatology providers in Indianaon file to place this against a meaningful peer group, so we don't.

Other procedural dermatology in Indianapolis

Where these figures come from

Is this you, or does something look wrong? →